Lloyd Klickstein, Versanis Bio CEO

A No­var­tis castoff drug gets new life at an At­las-backed start­up look­ing to blaze a trail in obe­si­ty

Af­ter decades of fail­ure, the obe­si­ty field is fi­nal­ly see­ing some ma­jor progress with the suc­cess of a sta­ble of GLP-1 di­a­betes drugs show­ing clin­i­cal ben­e­fit. A small biotech thinks it has some­thing new to of­fer in that space with an old­er drug, and in­vestors like what they see so far.

Ver­sa­nis Bio launched Tues­day with a $70 mil­lion A round backed by biotech blue-chip­pers At­las Ven­ture and Medicxi with lead can­di­date bima­grum­ab, an in-li­censed No­var­tis drug orig­i­nal­ly tar­get­ing mus­cle weak­ness, gear­ing up for a Phase II study in obe­si­ty.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA